• Kyverna Therapeutics flagged new one-year results from its KYSA-8 registrational trial of miv-cel in stiff person syndrome.
• Data will be presented at MSToronto2026 on Oct. 21, 2026, pointing to sustained clinical benefit with a well-tolerated safety profile.
• Updated Phase 1 investigator-initiated findings in progressive multiple sclerosis will be presented on Oct. 23, 2026, showing encouraging early activity.
• Management indicated it is working to complete a BLA in its initial indication this quarter, a key step toward a potential first approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070800PRIMZONEFULLFEED9841094) on October 07, 2026, and is solely responsible for the information contained therein.